Earning Analysis
Welcome to our in-depth analysis of Immunovant Inc(IMVT) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of Immunovant Inc earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency:
Actual
Estimate
Surprise Analysis
| FY2026Q2 | 2025-11-10 | Pre-Market | -0.72 | -0.73 | -1.39 | 86.38M | 0.00 | -100.00 | +0.09 | -2.27 |
| - | 2024-08-08 | Pre-Market | -0.54 | - | - | - | - | - | +4.23 | +11.79 |
| FY2025Q1 | 2024-08-06 | - | -0.52 | -0.60 | -15.38 | 79.32M | - | - | +4.27 | +10.97 |
| FY2024Q4 | 2024-05-29 | - | -0.43 | -0.52 | -20.93 | - | - | - | +4.05 | -11.22 |
| FY2024Q3 | 2024-02-12 | - | -0.44 | -0.36 | +18.18 | - | - | - | +3.35 | +4.59 |
| FY2024Q2 | 2023-11-09 | - | -0.46 | -0.45 | +2.17 | - | - | - | -6.23 | +2.55 |
| FY2024Q1 | 2023-08-10 | - | -0.44 | -0.47 | -6.82 | - | - | - | +6.69 | -1.34 |
| - | 2023-05-22 | - | -0.48 | -0.46 | +4.17 | - | - | - | +11.98 | -0.75 |
| - | 2023-02-03 | - | -0.41 | -0.49 | -19.51 | - | - | - | -2.95 | +1.53 |
| - | 2022-08-05 | - | -0.40 | -0.35 | +12.50 | - | - | - | +8.68 | +20.78 |
IMVT Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, Immunovant Inc reported performance for FY2026Q2, announced on 2025-11-10. The company achieved an EPS of -0.73, compared to analyst estimates of -0.72 by -1.39% . Revenue for the quarter reached 0.00 compared to expectations of 86.38M by -100.00% .
The stock price reacted with a 0.09% one-day change and a -2.27% five-day change following the earnings release. These movements reflect market reaction in Immunovant Inc growth trajectory and strategic initiatives.
IMVT Earnings Forecast
Looking ahead, Immunovant Inc(IMVT) remains a focal point for investors seeking growth opportunities. Analyst forecasts for project quarter revenue of and an EPS of -0.70.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for have been Go Up by 33.66%, while EPS estimates have been No Change by %. For the upcoming , revenue estimates have been adjusted No Change by % . These revisions correlate with a % change in stock price over the same period, suggesting potential buying opportunities for investors who believe in Immunovant Inc long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between IMVT's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Stock Price
Go Up
+33.66%
In Past 3 Month
1Y
3Y
5Y
Fiscal Period
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-:0
--
EPS Estimate-:0
—
Stock Price22.91
IMVT Revenue and EPS Performance: A Historical Perspective
Immunovant Inc revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2026Q2 (2025-11-10,Pre-Market):
EPS: -0.73 (Actual) vs.-0.72 (Estimate) (-1.39%)
Revenue: 0.00 (Actual) vs. 86.38M (Estimate) (-100.00%)
Price Reaction: 0.09%(1-Day), -2.27%(5-Day)
(2024-08-08,Pre-Market):
EPS: (Actual) vs.-0.54 (Estimate) (%)
Revenue: 0.00 (Actual) vs. 0.00 (Estimate) (%)
Price Reaction: 4.23%(1-Day), 11.79%(5-Day)
FY2025Q1 (2024-08-06,):
EPS: -0.60 (Actual) vs.-0.52 (Estimate) (-15.38%)
Revenue: 0.00 (Actual) vs. 79.32M (Estimate) (%)
Price Reaction: 4.27%(1-Day), 10.97%(5-Day)
Earnings Reaction
The chart below shows how IMVT performed 10 days before and after its earnings report, based on data from the past quarters. Typically, IMVT sees a -1.72% change in stock price 10 days leading up to the earnings, and a +3.44% change 10 days following the report. On the earnings day itself, the stock moves by +3.42%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in SEP/2025, the stock changed -2.05% on the day following the earnings release and then changed by -0.21% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
Immunovant Inc (IMVT) Q2 2025 Earnings Call Summary
Neutral
2025-11-12
The earnings call summary indicates a mixed sentiment. While there are positive aspects like potential market opportunities and a strong capitalization, concerns arise from litigation uncertainties, lack of clear guidance, and competitive pressures. The Q&A reveals cautious optimism but lacks concrete data to support strong positive sentiment. Given the market cap, the overall sentiment is neutral, suggesting limited short-term stock price movement.
Immunovant Inc (IMVT) Q2 2026 Earnings Call Summary
Positive
2025-11-10
The earnings call summary indicates a positive outlook with strong financial performance, optimistic product development updates, a solid market strategy, and shareholder return plans. The Q&A section reveals management's confidence in their competitive positioning and strategic initiatives, despite some litigation uncertainties. Considering the company's market cap and the overall positive sentiment, the stock is likely to see a positive movement of 2% to 8%.
People Also Watch
FAQ
What were the key highlights of IMVT’s latest earnings report for FY2026Q2?
How did IMVT’s stock price react after the FY2026Q2 earnings release?
What are the revenue and EPS estimates for IMVT for undefined?
How does IMVT’s stock price correlate with earnings forecast revisions?
What should investors expect from IMVT’s next earnings report?